Dr. Frank Harrell and Dr. C. Michael Gibson talk about the FDA’s new draft guidance on using Bayesian methods in clinical trials—and it could be a game changer.

By allowing researchers to combine prior data with new trial results, these approaches can speed up decision-making, reduce costs, and bring effective treatments to patients faster.

Especially impactful for rare diseases and pediatric studies, where every data point counts.

Smarter trials. Faster answers. Better outcomes.

Disclosures: TBD